CYTOMED THERAPEUTICS LTD (GDTC)
SGXZ17669631 - Common Stock
CYTOMED THERAPEUTICS LTD
NASDAQ:GDTC (1/8/2025, 8:04:56 PM)
After market: 2.04 -0.25 (-10.92%)2.29
-0.67 (-22.64%)
Company Profile
CytoMed Therapeutics Ltd. operates as a biopharmaceutical company. The company employs 34 full-time employees The company went IPO on 2023-04-14. The company is focused on harnessing its licensed proprietary technologies to create cell-based immunotherapies for the treatment of human cancers. The development of its technologies has been inspired by the clinical success of existing CAR-T in treating hematological malignancies as well as the clinical limitations and commercial challenges in extrapolating the CAR-T principle into treatment of solid tumors. Its product candidates include CTM-N2D, iPSC-gdNKT and CTM-GDT. CTM-N2D is a lead product candidate that consists of expanded gamma delta T cells grafted with NKG2DL-targeting CAR to enhance anti-cancer cytotoxicity. The iPSC-gdNKT product candidate utilizes iPSC as a starting material to generate gdNKT, which is a synthetic hybrid of a gamma delta T cell and a NK cell. The CTM-GDT product candidate consists of expanded allogeneic gamma delta T cells. The company also focuses on Off-the-shelf Donor-derived Gamma Delta T Cells Technology.
Company Info
CYTOMED THERAPEUTICS LTD
#08-22 One Commonwealth, 1 Commonwealth Lane
Singapore
P: 65603824911
Employees: 34
Website: https://www.cytomed.sg/
GDTC News
3 days ago - ChartmillTop movers in Monday's after hours sessionWhich stocks are moving after the closing bell on Monday?
3 days ago - CYTOMED THERAPEUTICS LIMITEDCytoMed Therapeutics signs Business & Research Collaboration Agreement with India’s SunAct Cancer Institute Private Limited to advance use of allogeneic off-the-shelf Gamma Delta T Cells for treatment of solid cancers in a proposed Phase 2 clinical trial2 months ago - CYTOMED THERAPEUTICS LIMITEDUpdate on Clinical Milestone - CytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies2 months ago - CYTOMED THERAPEUTICS LIMITEDUpdate on Clinical Milestone - CytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological MalignanciesSINGAPORE, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Further to an announcement on October 7, 2024, CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or...
3 months ago - CYTOMED THERAPEUTICS LIMITEDCytoMed Therapeutics’ first-in-human Phase I ANGELICA clinical trial using its patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) against blood and solid tumors received co-funding support from the NMRC Clinical Trial GrantCompletion of cash acquisition of licenced cord blood bank expanding CytoMed’s strategy to cord blood-derived biologics through its subsidiary, LongevityBank Pte Ltd
3 months ago - CYTOMED THERAPEUTICS LIMITEDCytoMed Therapeutics’ first-in-human Phase I ANGELICA clinical trial using its patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) against blood and solid tumors received co-funding support from the NMRC Clinical Trial GrantCompletion of cash acquisition of licenced cord blood bank expanding CytoMed’s strategy to cord blood-derived biologics through its subsidiary,...
GDTC Twits
Here you can normally see the latest stock twits on GDTC, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
